Outpatient Service for Mid-trimester Termination of Pregnancy

Abortion in Second Trimester Clinical Trial

Official title:
Evaluating the Safety, Acceptability and Feasibility of an Outpatient "Day Procedure" Service Documenting the Roles of Health Workers in the Provision of Medical Abortion at 13-18 Weeks Gestation

Status Completed

Clinical Trial Summary

This study seeks to evaluate the safety, acceptability and feasibility of an outpatient "day procedure" for medical abortion at 13-18 weeks gestation. The study regimen will consist of a single dose of 200 mg mifepristone to be taken orally either at home or at the hospital, followed approximately 24 - 48 hours later with administration of 400 mcg misoprostol. Repeat doses of 400 mcg (two tablets) of misoprostol will be administered buccally every three hours until the abortion is achieved.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Abortion in Second Trimester

Clinical Trial Details

NCT number	NCT03346629
Study type	Interventional
Source	Gynuity Health Projects
Contact
Status	Completed
Phase	Phase 4
Start date	December 1, 2017
Completion date	December 31, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02235155` - Mifepristone and Misoprostol for Midtrimester Termination of Pregnancy in Uzbekistan	N/A
Completed	`NCT03710239` - OPIOID Study - Pain With Osmotic Dilators	N/A
Completed	`NCT05046041` - Assessing Outpatient 'Day Procedure' for Second-trimester Medical Abortion at Two Public Sector Hospitals in Nepal	Phase 4
Completed	`NCT01766388` - Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Armenia	N/A